New Weight Loss Drug Mazdutide Shows 14% Weight Reduction in Chinese Adults

This groundbreaking study represents a significant advance in obesity treatment, testing mazdutide—a novel dual-action drug that simultaneously targets GLP-1 and glucagon receptors. Unlike existing single-target medications, this approach may offer superior weight loss results.

Researchers conducted a rigorous 48-week phase 3 trial across multiple Chinese medical centers, enrolling 610 adults with BMI ≥28 or BMI 24-28 with weight-related health conditions. Participants received weekly injections of either 4mg mazdutide, 6mg mazdutide, or placebo.

The results were remarkable. At 32 weeks, participants lost 10% (4mg dose) and 12.6% (6mg dose) of their body weight versus minimal change with placebo. By 48 weeks, weight loss reached 11% and 14% respectively. Crucially, 82% of high-dose participants achieved clinically meaningful 5% weight loss, while nearly half lost 15% or more—levels typically seen only with bariatric surgery.

Beyond weight loss, mazdutide improved all measured cardiovascular and metabolic parameters, suggesting comprehensive health benefits. The safety profile was encouraging, with mostly mild-to-moderate gastrointestinal side effects and discontinuation rates under 2%.

These findings position mazdutide as a potentially game-changing obesity treatment, offering weight loss comparable to surgical interventions through a weekly injection. However, the study was limited to Chinese populations, and long-term safety data beyond 48 weeks remains unknown.